Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-05

FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Accord Healthcare, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Accord Healthcare, Inc. to market oxybutynin chloride as a generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxybutynin chloride (Oxybutynin chloride)

Snippet

SUPPL AP for OXYBUTYNIN CHLORIDE (OXYBUTYNIN CHLORIDE)